X4 Pharmaceuticals Provides Business and Clinical Development Update
Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections…
Pharmaceuticals, Biotechnology and Life Sciences
Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018. Richard Toselli,…
In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine…
Company Presents Four Studies at American Association for Cancer Research (AACR) Annual Conference Preclinical Data for Lead Asset Repotrectinib Continue…
RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections MENLO PARK, Calif.–(BUSINESS WIRE)–Recida…
LOS ANGELES & CASTRES, France–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement…
–Oral presentation highlights encouraging outcomes in patients with advanced renal cell carcinoma -Data supports continued clinical development with planned PT2977…
– Randomized, 12-Month, Pivotal Trial Evaluating the Safety and Efficacy of Patidegib Topical Gel to Reduce the Disease Burden of…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/conference?src=hash" target="_blank"gt;#conferencelt;/agt;–Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of…